Patents Assigned to Biomics Biotechnologies Co., Ltd.
-
Patent number: 10443057Abstract: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.Type: GrantFiled: July 22, 2015Date of Patent: October 15, 2019Assignee: Biomics Biotechnologies, Co., Ltd.Inventors: York Yuan Yuan Zhu, Tiejun Li
-
Patent number: 9820942Abstract: The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.Type: GrantFiled: March 6, 2013Date of Patent: November 21, 2017Assignee: BIOMICS BIOTECHNOLOGIES CO., LTD.Inventors: Jianxin Chen, Wei Peng, Tiejun Li, Hui Zhu, Yan Ni, Wenjian Feng
-
Patent number: 9777278Abstract: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.Type: GrantFiled: August 14, 2015Date of Patent: October 3, 2017Assignee: BIOMICS BIOTECHNOLOGIES CO., LTDInventors: Dong Liang, David Sweedler, Kunyuan Cui
-
Publication number: 20160053267Abstract: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.Type: ApplicationFiled: July 22, 2015Publication date: February 25, 2016Applicant: BIOMICS BIOTECHNOLOGIES CO., LTD.Inventors: York Yuan Yuan Zhu, Tiejun Li
-
Publication number: 20150299707Abstract: The present invention provides a PCR based high-throughput method for preparing full-sites siRNA polynucleotide pool, comprising: DNase I random digestion; Loop-1 phosphate linker ligation; single PCR amplification; a type III restriction/modification enzyme digestion; blunt ending; Loop-2 phosphate linker ligation; double primer PCR; FokI digestion and cloning into an siRNA expression vector. The present invention enables the use of a type III restriction/modification enzyme linkers mediated PCR method for high-throughput preparing an siRINA polynucleotide pool, in which the functional length of siRNAs can be controllably distributed from 19-23 bp, thus completely mimic the natural siRNA length diversity, specially suitable for RNAi therapeutic targets screening. The present invention overcomes the bottlenecks and drawbacks of conventional siRNA polynucleotide pool construction technologies.Type: ApplicationFiled: July 2, 2015Publication date: October 22, 2015Applicant: BIOMICS BIOTECHNOLOGIES CO., LTD.Inventor: York Yuan Yuan Zhu
-
Publication number: 20150272886Abstract: The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.Type: ApplicationFiled: March 6, 2013Publication date: October 1, 2015Applicant: BIOMICS BIOTECHNOLOGIES CO., LTD.Inventors: Jianxin Chen, Wei Peng, Tiejun Li
-
Patent number: 9115167Abstract: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.Type: GrantFiled: March 8, 2012Date of Patent: August 25, 2015Assignee: Biomics Biotechnologies Co., Ltd.Inventors: York YuanYuan Zhu, TieJun Li
-
Patent number: 8846895Abstract: The present invention discloses preparation and application of double-stranded RNA molecules stable in mammalian body fluids. The mammalian-body-fluid-stable RNA molecules disclosed in the present invention are comprised of only unmodified nucleotides. For the first time, the present invention discloses the applications of mammalian-body-fluid-stable RNA molecules for immunotherapy and siRNA drug development.Type: GrantFiled: March 29, 2011Date of Patent: September 30, 2014Assignee: Biomics Biotechnologies Co. Ltd.Inventors: Quan Du, Zicai Liang
-
Publication number: 20130296401Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: ApplicationFiled: October 27, 2011Publication date: November 7, 2013Applicants: BIOMICS BIOTECHNOLOGIES CO., LTD, BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, Lu YiXiang, Li TieJun, Sun YunCheng, Tang XiaoJun, Shan Li
-
Patent number: 8563710Abstract: The present invention relates to a modified oligonucleotide, its preparation and application. The invention eables stabilizing the oligonucleotide by introducing a relatively small amount of modified nucleotide at specific UA/UA and/or CA/UG and/or UG/CA site of the oligonucleotide, therefore to decrease the modification-related cytotoxicity and compromising effects on the biological activity.Type: GrantFiled: March 30, 2010Date of Patent: October 22, 2013Assignee: Biomics Biotechnologies Co., Ltd.Inventor: Zicai Liang
-
Publication number: 20120232126Abstract: This invention relates to interfering RNA (iRNA) molecules and their applications, especially multi-targets iRNA molecules and their applications. The said multi-targets iRNA molecules comprised of a sense strand annealed onto at least one antisense strand, each strand is at least 30 nucleotides in length, the sense or antisense strand has at least two segments, which can target at least two RNAs of different genes, or can target at least two portions of an RNA, and wherein the iRNA does not induce an interferon-response when transfected into a cell. The iRNA molecule can interfere with the translation procedure post-transcription, and the target gene is inhibited or blocked, the iRNA does not induce an interferon-response in vivo. The RNA molecules are the active ingredient in preparation of the drug which can regulate one or many genes function.Type: ApplicationFiled: March 8, 2012Publication date: September 13, 2012Applicant: Biomics Biotechnologies Co., LtdInventors: York YuanYuan Zhu, TieJun Li
-
Patent number: 8217163Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.Type: GrantFiled: September 20, 2010Date of Patent: July 10, 2012Assignee: Biomics Biotechnologies Co., Ltd.Inventors: York Yuan Yuan Zhu, Li Chen, TieJun Li, YiXiang Lu, YunCheng Sun, Jinkang Wang
-
Publication number: 20120088815Abstract: The present invention relates to a modified oligonucleotide, its preparation and application. The invention enables stabilizing the oligonucleotide by introducing a relatively small amount of modified nucleotide at specific UA/UA and/or CA/UG and/or UG/CA site of the oligonucleotide, therefore to decrease the modification-related cytotoxicity and compromising effects on the biological activity.Type: ApplicationFiled: March 30, 2010Publication date: April 12, 2012Applicant: BIOMICS BIOTECHNOLOGIES CO. LTDInventor: Zicai Liang
-
Publication number: 20120071542Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.Type: ApplicationFiled: September 20, 2010Publication date: March 22, 2012Applicant: Biomics Biotechnologies Co., LtdInventors: York YuanYuan Zhu, Li Chen, TieJun Li, YiXiang Lu, YunCheng Sun, Jinkang Wang